10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ELI LILLY & CO | |||
Ticker: LLY Fiscal Year: 2020 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2020 10-K (Filed: Feb 17, 2021) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | |
| Cash and Cash Equivalents, Period Increase (Decrease) [Abstract] | |||
| Cash Flows from Operating Activities | |||
| Net income | $ 6,193,700 | 8,318,400 | 3,232,000 |
| Adjustments to Reconcile Net Income to Cash Flows from Operating Activities: | |||
| Gain related to disposition of Elanco (Note 19) | 0 | (3,680,500) | 0 |
| Gain on sale of antibiotic business in China (Note 3) | 0 | (309,800) | 0 |
| Depreciation and amortization | 1,323,900 | 1,232,600 | 1,609,000 |
| Change in deferred income taxes | (134,500) | 62,400 | 326,800 |
| Stock-based compensation expense | 308,100 | 312,400 | 279,500 |
| Net investment gains | (1,438,500) | (403,100) | (27,000) |
| Acquired in-process research and development (Note 3) | 660,400 | 239,600 | 1,983,900 |
| Other non-cash operating activities, net | 333,900 | 751,800 | 499,000 |
| Other changes in operating assets and liabilities, net of acquisitions and divestitures: | |||
| Receivables(increase) decrease | (1,350,200) | (127,200) | (996,700) |
| Inventories(increase) decrease | (533,400) | (258,700) | 7,800 |
| Other assets(increase) decrease | (457,100) | (602,300) | (980,000) |
| Income taxes payableincrease (decrease) | 322,000 | (221,300) | (125,300) |
| Accounts payable and other liabilitiesincrease (decrease) | 1,271,300 | (477,700) | (284,500) |
| Net Cash Provided by Operating Activities | 6,499,600 | 4,836,600 | 5,524,500 |
| Cash Flows from Investing Activities | |||
| Purchases of property and equipment | (1,387,900) | (1,033,900) | (1,210,600) |
| Proceeds from sales and maturities of short-term investments | 129,700 | 136,600 | 2,552,500 |
| Purchases of short-term investments | (11,400) | (42,700) | (112,200) |
| Proceeds from sales of noncurrent investments | 757,100 | 609,800 | 3,509,500 |
| Purchases of noncurrent investments | (358,700) | (247,500) | (837,900) |
| Purchases of in-process research and development | (641,200) | (319,600) | (1,807,600) |
| Cash paid for acquisitions, net of cash acquired (Note 3) | (849,300) | (6,917,700) | 0 |
| Cash distributed to Elanco upon disposition | 0 | (374,000) | 0 |
| Cash received for sale of antibiotic business in China | 0 | 354,800 | 0 |
| Other investing activities, net | 102,800 | (248,700) | (187,700) |
| Net Cash Provided by (Used for) Investing Activities | (2,258,900) | (8,082,900) | 1,906,000 |
| Cash Flows from Financing Activities | |||
| Dividends paid | (2,687,100) | (2,409,800) | (2,311,800) |
| Net change in short-term borrowings | (1,494,200) | 995,400 | (2,197,900) |
| Proceeds from issuance of long-term debt | 2,062,300 | 6,556,400 | 2,477,700 |
| Repayments of long-term debt | (276,500) | (2,866,400) | (1,009,100) |
| Purchases of common stock | (500,000) | (4,400,000) | (4,150,700) |
| Net proceeds from Elanco initial public offering (Note 19) | 0 | 0 | 1,659,700 |
| Other financing activities, net | (241,600) | (200,100) | (372,800) |
| Net Cash Used for Financing Activities | (3,137,100) | (2,324,500) | (5,904,900) |
| Effect of exchange rate changes on cash and cash equivalents | 216,000 | (89,900) | (63,600) |
| Net increase (decrease) in cash and cash equivalents | 1,319,600 | (5,660,700) | 1,462,000 |
| Cash and cash equivalents at beginning of year (includes $677.5 (2019) and $324.4 (2018) of discontinued operations) | 2,337,500 | 7,998,200 | |
| Cash and Cash Equivalents at End of Year (includes $677.5 (2018) of discontinued operations) | 3,657,100 | 2,337,500 | 7,998,200 |
| External Links | |
| ELI LILLY & CO (LLY) Fiscal Year 2020 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |